Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS

5-n-Butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one (1b), a new non-peptide angiotensin type 1 receptor antagonist, has been observed to play a positive role in the treatment of hypertension in preclinical tests. Rats were dosed with the drug, and the major metabolites in the bile were separated by gradient elution high-performance liquid chromatography. HPLC-diode array detection-mass spectrometry, HPLC-electrospray ionization MS/MS methods in negative ion mode and collision-induced dissociation were used to elucidate the structures of the major metabolites of 1b. One dihydroxylated 1b (M1), two monohydoxylated 1b (M2, M3) and one 1b monoglucuronide (M5) were found in male rat bile; however, three monohydoxylated 1b (M2, M3, M4) and one 1b monoglucuronide (M5) were found in female rat bile. These metabolites greatly differ in amount between male and female rat bile.     

3-O-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪的合成与表征

利用6-(4-卤代苯基)-3(2H)-哒嗪酮的银盐(2)与2,3,4,6-四-O-乙酰基-1-溴-1-脱氧-α-D-吡喃葡萄糖(3)发生Koenigs-knorr反应, 合成了3-O-(2,3,4,6-四-O-乙酰基-β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪(4),4用干燥的氨气在0℃～-5℃下处理脱乙酰基保护基得相应的3-O-(β-D-吡喃葡萄糖-1-基)-6-(4-卤代苯基)哒嗪(5).其结构经元素分析,IR及1H NMR证实.     

Metabolism of 1-(3-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]-propyl)-3-(6-methoxypyridin-3-yl)-1-(2-trifluoromethylbenzyl)thiourea (YH3945), a novel anti-cancer drug, in rats using the 14C-labeled compound

The metabolism of a novel anti-cancer agent, 1-(3-[3-(4-cyanobenzyl)-3H-imidazol-4-yl]-propyl)-3-(6-methoxypyridin-3-yl)-1-(2-trifluoromethylbenzyl)thiourea (YH3945), was investigated in rats. Bile, plasma, feces, and urine were collected and analyzed by a high-performance liquid chromatography (HPLC) system equipped with ultraviolet (UV), mass spectrometric, and radioactivity detectors. After intravenous dosing, mean radiocarbon recovery was 74.4 +/- 1.3% with 62.4 +/- 1.2% in the feces and 12.0 +/- 0.5% in the urine. Biliary excretion of the radioactivity for the first 24 h period was approximately 32%, suggesting that YH3945 is cleared by hepatobiliary excretion. YH3945 was extensively metabolized to 21 different metabolites including glucuronide conjugates, and structures of the metabolites were elucidated based on MS(n) and NMR spectral analyses. The major metabolic pathways in the rat were identified as O-demethylation of methoxypyridine, N-debenzylation of imidazole, and hydroxylation. Cyclic metabolites were also identified; concomitant demethylation in the methoxypyridine moiety and hydroxylation at the C16 position might destroy the chemical stability of the compound and subsequently lead to non-enzymatic cyclization. Cyclic metabolites were characteristic of YH3945, and a non-enzymatic reaction mechanism for the formation of cyclic metabolites was postulated.     

N-甲氧基-N-{2-[2-取代-4-氯-3(2H)哒嗪酮-5-氧(硫)亚甲基]苯基}氨基甲酸甲酯的合成及其生物活性

2取代4氯5羟基(巯基)3(2H)哒嗪酮与N甲氧基N2溴甲苯氨基甲酸甲酯反应合成了一系列新型N甲氧基N{2[2取代4氯3(2H)哒嗪酮5氧(硫)亚甲基]苯基}氨基甲酸甲酯,其结构经1HNMR,IR和LCMS确认。生物活性测定表明,该类化合物在50mg·L-1下对稻瘟病菌,黄瓜灰霉,小麦赤霉病等具有较高的抑菌活性。     

Isomers of a dibismuthane, R2Bi-BiR2 [R = 2,6-(Me2NCH2)2C6H3], and unusual reactions with oxygen: formation of [R2Bi]2(O2) and R'R' 'Bi [R' = 2-(Me2NCH2)-6-{Me2N(O)CH2}C6H3; R' ' = 2-(Me2NCH2)-6-{O(O)C}C6H3

R2Bi-BiR2 [1; R = 2,6-(Me2NCH2)2C6H3], a dibismuthane that exists in different forms in the crystalline state, reacts in air with the formation of the peroxide [R(2)Bi]2(O2) (2) and partial oxidation of the pendant (dimethylamino)methyl groups, yielding the mononuclear bismuth complex R'R' 'Bi (3) [R' = 2-(Me2NCH2)-6-{Me2N(O)CH2}C6H3; R' ' = 2-(Me2NCH2)-6-{O(O)C}C6H3].     

Substitution, cage functionalization, and oxidation of the charge-compensated triruthenium monocarbollide cluster complex [1-SMe2-2,2-(CO)2-7,11-(mu-H)2-2,7,11-{Ru2(CO)6}-closo-2,1-RuCB10H8

The compound [1-SMe2-2,2-(CO)2-7,11-(mu-H)2-2,7,11-{Ru2(CO)6}-closo-2,1-RuCB10H8] 1a reacts with PMe3 or PCy3(Cy = cyclo-C6H11) to give the structurally different species [1-SMe2-2,2-(CO)2-7,11-(mu-H)2-2,7,11-{Ru2(CO)5(PMe3)}-closo-2,1-RuCB10H8] 4 and [1-SMe2-2,2-(CO)2-11-(mu-H)-2,7,11-{Ru2(mu-H)(CO)5(PCy3)}-closo-2,1-RuCB10H8]5, respectively. A symmetrically disubstituted product [1-SMe2-2,2-(CO)2-7,11-(mu-H)2-2,7,11-{Ru2(CO)4(PMe3)2}-closo-2,1-RuCB10H8] 6 is obtained using an excess of PMe3. In contrast, the chelating diphosphines 1,1'-(PPh2)2-Fe(eta-C5H4)2 and 1,2-(PPh2)2-closo-1,2-C2B10H10 react with 1a to yield oxidative-insertion species [1-SMe2-2,2-(CO)2-11-(mu-H)-2,7,11-{Ru2(mu-H)(micro-[1',1'-(PPh2)2-Fe(eta-C5H4)2])(CO)4}-closo-2,1-RuCB10H8] 7 and [1-SMe2-2,2-(CO)2-11-(mu-H)-2,7,11-{Ru2(mu-H)(CO)4(1',2'-(PPh2)2-closo-1',2'-C2B10H10)}-closo-2,1-RuCB10H8] 8, respectively. In toluene at reflux temperatures, 1a with Bu(t)SSBu(t) gives [1-SMe2-2,2-(CO)2-7-(mu-SBu(t))-11-(mu-H)-2,7,11-{Ru2(mu-H)(mu-SBu(t))(CO)4}-closo-2,1-RuCB10H8] 9, and with Bu(t)C [triple bond] CH gives [1-SMe2-2,2-(CO)2-7-{mu:eta2-(E)-CH=C(H)Bu(t)}-11-{mu:eta2-(E)-CH=C(H)Bu(t)}-2,7,11-{Ru2(CO)5}-closo-2,1-RuCB10H8] 10. In the latter, two alkyne groups have inserted into cage B-H groups, with one of the resulting B-vinyl moieties involved in a C-H...Ru agostic bond. Oxidation of 1a with I2 or HgCl2 affords the mononuclear ruthenium complex [1-SMe2-2,2,2-(CO)3-closo-2,1-RuCB10H10] 11.     

Syntheses of the metabolites of 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H benzimidazole difumarate (KG-2413) and related compounds

The metabolites of 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-b enzimidazole difumarate (KG-2413), which has a potent H1-antihistaminic activity, were predicted on the basis of metabolic studies of related compounds and were synthesized to aid in identification of the actual metabolites and for examination of their antihistaminic activity. Among the twelve compounds prepared, nine compounds were actually found as the metabolites of KG-2413 in rat urine. The antihistaminic activities of these metabolites were found to be lower than that of KG-2413.     

Synthesis of N-Aryl-2- (1'' , 6'' -dihydro-6'' -pyridazinone-3''-carbonyl) Thiosemicarbazides and Their Related Heterocyclic Compounds

1,6-Dihydro-3-hydrozinocarbonyl-6-pyridazinone(compound 2) were prepared from α-ketoglutaric acid and hydrazine hydrate. A series of N-aryl-2-(1' ,6'-dihydro-6'-pyridazinone-3'-earbonyl) thiosemicarbazides 3a-3f were synthesized from the reaction of aryl isothiocyanates with compound 2. The terminal compounds 1,3, 4-thiadiazole, 1,3,4-oxadiazole and 1,2, 4-triazol-5-thione derivatives were cyclized from compounds 3a-3f. Their structures were confirmed by IR, 1H NMR, MS and elemental analyses.     

Optically active antifungal azoles. XIII. Synthesis of stereoisomers and metabolites of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456)

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone [(1R,2R)-1: TAK-456] is a new antifungal agent selected as a candidate for clinical trials. The three stereoisomers [(1S,2R)-, (1S,2S)- and (1R,2S)-1] of this compound were prepared as authentic samples to determine the enantiomeric and diastereomeric purity of TAK-456 as well as to compare their in vitro antifungal activity. Pharmacokinetic studies of TAK-456 using rats identified the existence of metabolites in the liver homogenate. The structures of the major metabolites were assigned as 4-hydroxy-2-imidazolidinone (3) and/or 5-hydroxy-2-imidazolidinone (4), based on HPLC and LC/MS/MS analyses. These hydroxylated compounds, 3 and 4, were prepared by reduction of the corresponding imidazolidinediones, 11 and 12, and confirmed to be identical to the metabolites by HPLC. In vitro antifungal activities of the three stereoisomers and the synthesized metabolites were considerably weaker than TAK-456.     

Determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2h-1,4-benzodiazepin-2-one (Ro 7-9957) and its major biotransformation products in blood and urine by electron capture-gas-liquid chromatography.

A sensitive and specific electron capture-gas chromatographic assay was developed for the determination of 7-iodo-1,3-dihydro-1-methyl-5(2'-fluorophenyl)-2H-1,4-benzodiazepin-2-one (I) and its major metabolites in blood and urine. The overall recovery of I and its N-desmethyl metabolite (II) from blood is apparently quantitative. The recovery of the major urinary metabolite, the N-desmethyl-3-hydroxy analog (IV), and the minor metabolites, the N-desmethyl analog (II) and the N-methyl-3-hydroxy analog (III) added to urine as authentic reference standards ranged from 80 to 85%. The sensitivity limits of detection are of the order of 2-3 ng of I and 4-5 ng of II per ml of blood or urine. The method was applied to the determination of blood levels and the urinary excretion pattern in a dog following oral and intravenous administration of a 1-mg/kg dose (total 13 mg), and in man following the intravenous administration of single 5- and 10-mg doses. The N-desmethyl metabolite II was more predominant in dog blood than was the orally or intravenously administered I, but II was barely measurable in human blood.     

Mass spectrometric structure determination of metabolites of 3-[2-(N,N-dimethylaminomethyl)phenylthio]phenol

Metabolites of 3-[2-(N,N-dimethylaminoethyl)phenylthio]phenol (I) were isolated from the urine of rats, mice, rabbit and dog and from the faeces of rats by extraction and thin-layer chromatography. From the mass spectrum of I and using characteristics mass shifts in the spectra of metabolites, the structures of four metabolites were determined, whereas for two other isomeric metabolites the structures were resolved by means of IR spectra. Conclusions regarding the structures derived from the spectra were confirmed by comparing them with synthetic standards. Generally, metabolic changes of I can be characterized by demethylation, hydroxylation combined with methylation, S-oxidation and by a combination of these metabolic reactions.     

Reactions of the dianion [1,1,1-(CO)3-2-Ph-closo-1,2-MnCB9H9]2- with transition-metal cations: facile insertion and then extrusion of cluster vertexes

The manganacarborane dianion in [N(PPh(3))(2)][NEt(4)][1,1,1-(CO)(3)-2-Ph-closo-1,2-MnCB(9)H(9)] (1b) reacts with cationic transition metal-ligand fragments to give products in which the electrophilic metal groups (M') are exo-polyhedrally attached to the {closo-1,2-MnCB(9)} cage system via three-center two-electron B-H --> M' linkages and generally also by Mn-M' bonds. With {Cu(PPh(3))}(+), the Cu-Mn-Cu trimetallic species [1,6-{Cu(PPh(3))}-1,7-{Cu(PPh(3))}-6,7-(mu-H)(2)-1,1,1-(CO)(3)-2-Ph-closo-1,2-MnCB(9)H(7)] (3a) is formed, whereas reactions with {M'(dppe)}(2+) (M' = Ni, Pd; dppe = Ph(2)PCH(2)CH(2)PPh(2)) give [1,3-{Ni(dppe)}-3-(mu-H)-1,1,1-(CO)(3)-2-Ph-closo-1,2-MnCB(9)H(8)] (5a) and [1,3,6-{Pd(dppe)}-3,6-(mu-H)(2)-1,1,1-(CO)(3)-2-Ph-closo-1,2-MnCB(9)H(7)] (5b), both of which contain M'-Mn bonds. The latter reaction with M' = Pt affords [3,6-{Pt(dppe)}-3,6-(mu-H)(2)-1,1,1-(CO)(3)-2-Ph-closo-1,2-MnCB(9)H(7)] (6), which lacks a Pt-Mn connectivity. Compound 6 itself spontaneously converts to [1-Ph-2,2,2-(CO)(3)-8,8-(dppe)-hypercloso-8,2,1-PtMnCB(9)H(9)] (7b) and thence to [3,6,7-{Mn(CO)(3)}-3,7-(mu-H)(2)-1-Ph-6,6-(dppe)-closo-6,1-PtCB(8)H(6)] (8). This sequence occurs via initial insertion of the {Pt(dppe)} unit and then extrusion of {Mn(CO)(3)} and one {BH} vertex. In the presence of alcohols ROH, compound 6 is transformed to the 7-OR substituted analogues of 7b. X-ray diffraction studies were essential in elucidating the structures encountered in compounds 5-8 and hence in understanding their behavior.     

Darstellung und spektroskopische Charakterisierung von Kupfer(II)- und Nickel(II)-tricyanmethanid-Komplexen mit Imidazol-Derivaten – Kristallstruktur von [Cu{C(CN)3}2(2-meiz)2]

Synthesis and Spectroscopic Characterization of Copper(II) and Nickel(II) Tricyanomethanide Complexes with Imidazoles – Crystal Structure of [Cu{C(CN)₃}₂(2-meiz)₂] The copper(II) and nickel(II) tricyanomethanide complexes with imidazoles of the type [Cu{C(CN)₃}₂L₄], [L = 2- or 4-methylimidazole (meiz)] and [M{C(CN)₃}₂L₂] [M = Cu, L = imidazole (iz), 2- or 4-meiz; M = Ni, L = iz, 2- or 4-meiz] were prepared and characterized by electronic, infrared, and – some of them – by ESR spectroscopy. The structure [Cu{C(CN)₃}₂(2-meiz)₂], solved by X-ray crystallographic analysis, shows a two-dimensional network with unsymmetric C(CN)₃-bridges between the Cu^II atoms. Polymeric structures with bridging C(CN)₃-groups were identified by means of spectroscopic methods also for the other [M{C(CN)₃}₂L₂] complexes. On the other hand, for the complexes [M{C(CN)₃}₂L₄] follow molecular structures, in which monodentate C(CN)₃ ligands are present. All compounds under investigation show a tetragonal-bipyramidal geometry with various degree of tetragonal distortion.     

Facile hydrometalation of alkynes by nido-1,2-(CpRuH)(2)B(3)H(7) yielding novel Ru-B edge-bridging alkylidenes. Stepwise conversion of HCtbd1;CC(O)OMe into nido-1,2-(CpRuH)(2)-3-HOB-4-MeC-5-MeOC-BH(3), Cp = eta(5)-C(5)Me(5)

The reaction of the alkyne HCCC(O)OMe with 7 sep 1,2-(Cp*RuH)2B3H7 leads to hydroboration plus hydroruthenation to produce nido-1,3-mu-Me{C(O)OMe}C-1,2-(Cp*Ru)2B3H7, a compound with an exocluster ruthenium-boron mu-alkylidene that exists in two isomeric forms. Both isomers undergo rearrangement with intramolecular chelation of the carbonyl oxygen at a boron site, thereby opening the cluster and generating arachno-2,3,-mu(C)-5-eta1(O)-Me{C(O)OMe}C-1,2-(Cp*Ru)2B3H7. Further heating leads to deoxygenation of the carbonyl fragment by a boron center concurrent with insertion of the carbon atom into the metallaborane cage to give nido-1,2-(Cp*RuH)2-3-HOB-4-MeC-5-MeOC-BH3.     

New members of a class of dinitrosyliron complexes (DNICs): interconversion and spectroscopic discrimination of the anionic {Fe(NO)2}9 [(NO)2Fe(C3H3N2)2]- and [(NO)2Fe(C3H3N2)(SR)]- (C3H3N2 = deprotonated imidazole; R = tBu, Et, Ph)

The anionic {Fe(NO)2}(9) DNIC[(NO)2Fe(C3H3N2)2](-) (2) (C3H3N2 = deprotonated imidazole) containing the deprotonated imidazole-coordinated ligands and DNICs [(NO)2Fe(C3H3N2)(SR)](-) (R = (t)Bu(3), Et(4), Ph(5)) containing the mixed deprotonated imidazole-thiolate coordinated ligands, respectively, were synthesized by thiol protonation or thiolate(s) ligand-exchange reaction. The anionic {Fe(NO)2}(9) DNICs 2- 5 were characterized by IR, UV-vis, EPR, and single-crystal X-ray diffraction. The facile transformation among the anionic {Fe(NO)2}(9) DNICs 2- 5 and [(NO)2Fe(S(t)Bu)2](-)/[(NO)2Fe(SEt)2](-)/[(NO)2Fe(SPh)2](-) was demonstrated in this systematic study. Of importance, the distinct electron-donating ability of thiolates serve to regulate the stability of the anionic {Fe(NO)2}(9) DNICs and the ligand-substitution reactions of DNICs. At 298 K, DNIC 2 exhibits the nine-line EPR signal with g = 2.027 (aN(NO) = 2.20 and aN(Im-H) = 3.15 G; Im-H = deprotonated imidazole) and DNIC 3 displays the nine-line signals with g = 2.027 (aN(NO) = 2.35 and aN(Im-H) = 4.10 G). Interestingly, the EPR spectrum of complex 4 exhibits a well-resolved 11-line pattern with g = 2.027 (aN(NO) = 2.50, aN(Im-H) = 4.10 G, and aH = 1.55 G) at 298 K. The EPR spectra (the pattern of hyperfine splitting) in combination with IR nu NO spectra (DeltanuNO = the separation of NO stretching frequencies, DeltanuNO = approximately 62 cm (-1) for 2 vs approximately 50 cm(-1) for 3- 5 vs approximately 43 cm(-1) for [(NO)2Fe(S(t)Bu)2](-)/[(NO)2Fe(SEt)2](-)/[(NO)2Fe(SPh)2](-)) may serve as an efficient tool for the discrimination of the existence of the anionic {Fe(NO)2}(9) DNICs containing the different ligations [N,N]/[N,S]/[S,S].     

{H(3-(t)Bupz)B(3-(t)Bupz)(2)-eta(2)}AlEt(2) and {H(3-(t)Bupz)B(3-(t)Bupz)(5-(t)Bupz)-eta(2)}AlEt(2). Structure, Dynamic Solution Behavior, and the 1,2-Borotropic Shift

HB(3-(t)Bupz)(3)Tl and AlEt(3) in benzene yield {H(3-(t)Bupz)B(3-(t)Bupz)(2)-eta(2)}AlEt(2), 1, as a hydrocarbon-soluble crystalline solid. Compound 1 is also obtained in a related reaction involving ClAlEt(2) via a preferential metathesis of the Al-Cl bond. Crystal data for 1 at -101 degrees C: a = 11.770(3) ?, b = 11.054(3) ?, c = 21.973(6) ?, beta = 95.57(1) degrees, Z = 4, space group P2(1)/a. In 1 the Al center is four-coordinate with Al-C = 1.97(1) ? and Al-N = 1.99(1) ? and with C-Al-C = 127 degrees and N-Al-N = 101 degrees being the largest and smallest angles, respectively. The average N-B-N angle is 109(1) degrees. In toluene-d(8) and tetrahydrofuran-d(8), 1 shows two types of 3-(t)Bupz groups in the integral ratio 2:1 and two distinct ethyl ligands. At low temperature there is a broadening of the 3-(t)Bupz singlet that is assigned to the eta(2)-(t)Bupz ligands. Up to +60 degrees C, compound 1 is nonfluxional on the NMR time scale but does isomerize to {H(3-(t)Bupz)B(3-(t)Bupz)(5-(t)Bupz)-eta(2)}AlEt(2), 2. Crystal data for 2 at -172 degrees C: a = 29.235(5) ?, b = 11.298(1) ?, c = 22.033(3) ?, beta = 129.66(1) degrees, Z = 8, space group = C2/c. In 2 there is a pseudotetrahedral Al center with Al-C = 1.97(1) ? (average) and Al-N = 1.95(1) ? (average) and with C-Al-C = 119 degrees and N-Al-N = 98 degrees as the largest and smallest angles, respectively. The average N-B-N angle is 108(1) degrees. In 2 the eta(2)-tris(alkylpyrazolyl)borate ligand isomerizes by a 1,2-borotropic shift to give one 5-(t)Bupz fragment that is part of the eta(2)-N,N' aluminum-bonded ligand. Variable-temperature (1)H NMR spectra of 2 in toluene-d(8) and THF-d(8) reveal temperature-dependent exchange involving the 3-(t)Bupz moieties, with more rapid site exchange in toluene-d(8) than in THF-d(8). At low temperature there are two ethyl signals, one of which indicates diastereotopic methylene protons, as well as three (t)Bu signals in the ratio 1:1:1. The dynamic behavior of 2 is consistent with an eta(2) right harpoon over left harpoon eta(3) exchange process as opposed to an eta(2) right harpoon over left harpoon eta(1) exchange wherein the Al center is transiently three-coordinate. The isomerization of 1 to 2 has been studied in benzene-d(6) (DeltaH() = 21.0(2) kcal/mol, DeltaS() = -15(1) eu) and THF-d(8) (DeltaH() = 18.3(4) kcal/mol, DeltaS() = -15(1) eu) and compared to a related isomerization involving {H(2)B(3-(t)Bupz)(2)-eta(2)}AlMe(2) reported by Parkin and Looney [Polyhedron 1990, 9, 265] in benzene-d(6) (DeltaH() = 34.5(8) kcal/mol, DeltaS() = 6(2) eu). It is proposed that the rate-determining 1,2-borotropic shift in the 1 --> 2 reaction occurs in a noncoordinating (t)Bupz group and that this is followed by a rapid associative interchange of pz groups wherein the sterically less demanding 5-(t)Bupz moiety remains bound to the metal.     

Preparations of bis[2-(2-arylethynyl)-3-thienyl]arenes and bis[2-{2-(trimethylsilyl)ethynyl}-3-thienyl]arenes

4,4′-Bis[2-(2-phenylethynyl)-3-thienyl]biphenyl, 4,4′-bis[2-{2-(trimethylsilyl)ethynyl}-3-thienyl]biphenyl and their congeners were prepared and their properties were studied. Extension of π-system through the central benzene ring was suggested by UV-vis spectra. Connection of two 1,4-bis[2-{2-(trimethylsilyl)ethynyl}-3-thienyl]benzene units was exemplified.     

Lithiation of 3-(Acylamino)-2-unsubstituted-, 3-(Acylamino)-2-ethyl-, and 3-(Acylamino)-2-propyl-4(3H)-quinazolinones: Convenient Syntheses of More Complex Quinazolinones(1)

3-(Pivaloylamino)- and 3-(acetylamino)-4(3H)-quinazolinones react with alkyllithium reagents to give 1,2-addition products in very good yields. Lithiation takes place with LDA and is regioselective at position 2. The lithium reagents thus obtained react with a variety of electrophiles to give the corresponding substituted derivatives in very good yields. Reactions of the lithium reagents with iodine give oxidatively dimerized cyclic structures. 3-(Pivaloylamino)- and 3-(acetylamino)-2-ethyl-4(3H)-quinazolinones and 3-(pivaloylamino)- and 3-(acetylamino)-2-propyl-4(3H)-quinazolinones are lithiated at the benzylic position with LDA. The lithium reagents so produced also react with a variety of electrophiles to give the corresponding 2-substituted-4(3H)-quinazolinone derivatives in very good yields. However, lithiation of 3-(acylamino)-2-(1-methylethyl)-4(3H)-quinazolinones was unsuccessful, as were lithiations of compounds having a diacetylamino group at position 3. The amide groups have been cleaved in good yield under basic or acidic conditions from some of the products to provide access to the free amino compounds.     

Unusual reactivity of a sterically hindered diphosphazane ligand, EtN{P(OR)(2)}(2), (R = C(6)H(3)(Pr(I))(2)-2,6) towards (eta(3)-allyl)palladium precursors

The reactivity of (eta(3)-allyl)palladium chloro dimers [(1-R-eta(3)-C(3)H(4))PdCl](2) (R = H or Me) towards a sterically hindered diphosphazane ligand [EtN{P(OR)(2)}(2)] (R = C(6)H(3)(Pr(i))(2)-2,6), has been investigated under different reaction conditions. When the reaction is carried out using NH(4)PF(6) as the halide scavenger, the cationic complex [(1-R-eta(3)-C(3)H(4))Pd{EtN(P(OR)(2))(2)}]PF(6) (R = H or Me) is formed as the sole product. In the absence of NH(4)PF(6), the initially formed cationic complex, [(eta(3)-C(3)H(5))Pd{EtN(P(OR)(2))(2)}]Cl, is transformed into a mixture of chloro bridged complexes over a period of 4 days. The dinuclear complexes, [(eta(3)-C(3)H(5))Pd(2)(mu-Cl)(2){P(O)(OR)(2)}{P(OR)(2)(NHEt)}] and [Pd(mu-Cl){P(O)(OR)(2)}{P(OR)(2)(NHEt)}](2) are formed by P-N bond hydrolysis, whereas the octa-palladium complex [(eta(3)-C(3)H(5))(2-Cl-eta(3)-C(3)H(4))Pd(4)(mu-Cl)(4)(mu-EtN{P(OR)(2)}(2))](2), is formed as a result of nucleophilic substitution by a chloride ligand at the central carbon of an allyl fragment. The reaction of [EtN{P(OR)(2)}(2)] with [(eta(3)-C(3)H(5))PdCl](2) in the presence of K(2)CO(3) yields a stable dinuclear (eta(3)-allyl)palladium(I) diphosphazane complex, [(eta(3)-C(3)H(5))[mu-EtN{P(OR)(2)}(2)Pd(2)Cl] which contains a coordinatively unsaturated T-shaped palladium center. This complex exhibits high catalytic activity and high TON's in the catalytic hydrophenylation of norbornene.